Sysmex Corp is primarily active in the healthcare and medical technology industries.

The main competitors of Sysmex Corp in the market include Abbott Laboratories, Siemens Healthineers, and Becton, Dickinson and Company (BD).

Sysmex Corp is a renowned healthcare company specializing in diagnostic solutions for medical organizations. Founded in 1968, Sysmex Corp has since achieved global recognition for its advanced technologies and commitment to improving medical diagnoses and treatments. The company offers a wide range of innovative products, including automated clinical laboratory systems, reagents, and software. Sysmex Corp has established itself as a leader in the field of blood and urinalysis testing, leveraging cutting-edge research and partnerships to enhance patient care. With a rich history spanning several decades, Sysmex Corp continues to revolutionize the healthcare industry with its strategic advancements and dedication to improving medical outcomes worldwide.

Sysmex Corp has achieved several significant milestones throughout its history. Some of these achievements include the development of the world's first automated blood coagulation analyzer, the introduction of the first fully automated urine sediment analyzer, and the establishment of international subsidiaries to expand its global presence. Sysmex Corp has also made advancements in the field of hematology, with the production of automated blood cell analyzers that provide accurate and efficient results. Additionally, the company has received recognition for its contributions to healthcare, such as the Japan Medical Device Excellence Award. Overall, Sysmex Corp's commitment to innovation and quality has led to various notable milestones in the medical technology industry.

Sysmex Corp is primarily present in various countries and regions across the globe. Some of the key markets where Sysmex Corp has a significant presence include Japan, the company's home country, where it is headquartered. Sysmex Corp also has a strong foothold in the Asia-Pacific region, particularly in China, South Korea, and India. Furthermore, Sysmex Corp has expanded its operations and established a notable presence in North America, primarily in the United States. Additionally, Sysmex Corp has a growing presence in Europe, with key markets such as Germany, France, and the United Kingdom.

Sysmex Corp represents values of integrity, innovation, and collaboration. With a strong corporate philosophy that revolves around contributing to the advancement of healthcare, Sysmex Corp is committed to providing reliable and efficient diagnostic solutions. The company prioritizes sustainable growth, social responsibility, and customer satisfaction. Through their cutting-edge technologies and solutions in the field of laboratory testing, Sysmex Corp aims to improve patient outcomes and enhance overall healthcare globally. With their dedication to excellence and continuous improvement, Sysmex Corp has established itself as a trusted leader in the healthcare industry.

Analysts currently set an average price target of 2.391,26 JPY for the Sysmex stock (median: 2.320,50 JPY), implying +28,1 % versus the latest price. The consensus is based on 21 analyst ratings.

Sysmex Analytikerens Kursmål 2026

21 analysts currently rate the Sysmex stock: 16 recommend buying, 5 holding and 0 selling. For 2026, analysts expect Sysmex to generate revenue of 498,17 Mrd. JPY and earnings per share of 64,06 JPY.

Sysmex Analytikerens Kursmål 2026

Converted at the current exchange rate, the Sysmex share trades at 10,25 EUR (1.888,50 JPY).

The Sysmex share (6869.T) is listed on 4 stock exchanges, including: Frankfurt (0YX.F), München (0YX.MU).

Sysmex Corp is a Japanese manufacturer of medical diagnostic devices and systems. The company is a global leader in the development and production of hematology and urine analysis devices, coagulation analysis devices, immunoassay systems, cell imaging devices, and laboratory automation solutions. The company is divided into three business segments: Diagnostic Business, Life Science Business, and IT Business. The Diagnostic Business focuses on the development and production of hematology and urine analysis devices and coagulation analysis devices, which are used in various medical fields such as hematology, oncology, pediatrics, and intensive care medicine. The Life Science Business includes immunoassay systems, cell imaging devices, and laboratory automation solutions, which are used in research and development, diagnostics, and drug development. The IT Business provides IT-based solutions for the medical fields served by the other business segments, aiming to efficiently collect and process data. Sysmex Corp is known for its research and development efforts, as well as its manufacturing capabilities, and it has established itself as an important player in the global healthcare industry. The company has a strong presence in international markets, with branches in over 190 countries. Sysmex Corp has partnerships with leading companies in the medical and pharmaceutical industries, allowing it to further strengthen and expand its position in the market. The company has a customer-oriented approach and strives to meet the needs of its clients. Overall, Sysmex Corp has revolutionized and modernized various medical fields with its unique products and services, making a significant contribution to the global healthcare industry.

forventet-omsætningen for Sysmex er 498,17 Mrd. JPY. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.

forventet-overskuddet for Sysmex er 39,94 Mrd. JPY. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.

Pris-til-indtjening-forholdet (P/E) for Sysmex er i øjeblikket 29,48. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Sysmex-aktien.

Pris-til-salgs-forholdet (P/S) for Sysmex er i øjeblikket 2,36. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Sysmex-aktien.

AlleAktien-kvalitetsscore for Sysmex er 8/10.

ISIN for Sysmex er JP3351100007. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.

WKN for Sysmex er 897966. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.

Tickeren for Sysmex er 6869.T. Tickersymbolet bruges til at handle Sysmex-aktier på børsen.

I løbet af de seneste 12 måneder udbetalte Sysmex en dividende på 35,00 JPY . Dette svarer til et dividendeafkast på ca. 1,85 %. For de kommende 12 måneder forventes Sysmex at udbetale en dividende på 64,92 JPY.

Dividendeudbytteprocenten for Sysmex er i øjeblikket 1,85 %.

Sysmex udbetaler dividende, som udloddes i månederne , , , .

Sysmex har udbetalt dividende hvert år i de seneste 30 år.

For de kommende 12 måneder forventes dividender på 64,92 JPY. Dette svarer til et dividendeafkast på 3,44 %.

Sysmex er klassificeret i sektoren 'Sundhed'.

For at modtage den seneste dividende fra Sysmex fra på 18 JPY, skulle du have aktien i din portefølje før ex-datoen den .

Sidste dividende blev udbetalt den .

I året 2025 blev Sysmex 28 JPY udbetalt som dividender.

Dividenderne fra Sysmex udloddes i JPY.